Eupraxia Pharmaceuticals Inc Ordinary Shares EPRX 深 沪
已收盘 10-31 16:00:00 美东时间
5.54
+0.210
+3.94%
华盛通- 最 高5.65
- 今 开5.41
- 成交量 6303股
- 最 低 5.40
- 昨 收 5.33
- 总市值 2.80亿
- 52周最高 7.19
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 2.6801
- 委 比 0.00%
- 总股本 5059.59万
- 历史最高 7.19
- 量 比 0.15
- 振 幅 4.69%
- 历史最低 2.20
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering
Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an update. On September 2...
09-30 05:06
Eupraxia Pharmaceuticals Reports Results With 8mg Dose In RESOLVE Trial; Patients In Cohort 9 Experienced The Largest Improvements In Tissue Health Outcomes And Eosinophil Reduction Observed To Date; Expands Phase 2b EP-104GI Study And Plans New GI Indication Trial In 2026
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial.Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date.RESOLVE Safety Committee and members of the Eupraxia Clinica
09-30 05:03
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Eupraxia Pharmaceuticals reported positive results from Cohort 9 of its RESOLVE trial for EP-104GI, showing the highest dose (8mg per injection) achieved the greatest improvements in tissue health and eosinophil reduction without serious adverse events. The company plans to expand the Phase 2b trial, increasing patient numbers from 60 to at least 120, and initiate a new GI indication trial in early 2026. A webinar on October 1st will provide furt...
09-29 21:00
Eupraxia Pharma将公开发行1270万股筹集约7000万美元
Eupraxia Pharmaceuticals（NASDAQ：EPRX）将其1270万股公开发行价格定为每股5.50美元，筹集约7000万美元。所筹资金将...
09-23 23:21
Eupraxia Pharmaceuticals prices $70M share offering
Eupraxia Pharmaceuticals (NASDAQ:EPRX) priced its previously announced public offering of 12.7M common shares at a price to the public of $5.50 per common share for gross proceeds of ~$70 million. In ...
09-23 14:38
Eupraxia Pharmaceuticals Announces Proposed Public Offering Of Common Shares; No Terms Disclosed
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,
09-23 04:01
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
Eupraxia Pharmaceuticals Inc. announced the pricing of its public offering of 12,727,273 common shares at US$5.50 per share, raising approximately US$70 million. The offering includes an option for underwriters to purchase an additional 1,909,090 shares. Proceeds will be used for advancing the product pipeline, completing preclinical studies and clinical trials, regulatory submissions, commercial preparation, and other corporate purposes. Cantor ...
09-23 02:42
Eupraxia Pharmaceuticals Reports Promising 1-Year Results for EoE Treatment
Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an announcement. Eupraxia P...
09-02 20:44
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
Eupraxia Pharmaceuticals reports positive Phase 1b/2a data for EP-104GI in treating eosinophilic esophagitis (EoE). Cohort 5 patients showed 2/3 remained in clinical remission at 12 months, with sustained tissue health improvements via EoE Histological Scoring System. No serious adverse events or candidiasis were reported. The drug demonstrated durable relief, with 67% SDI remission at 52 weeks for 4mg dose groups, and steady pharmacokinetics ove...
09-02 12:00
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $12 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $12 price target.
08-20 18:33
